Trial reportThe New England journal of medicine2016
Interim Buprenorphine vs. Waiting List for Opioid Dependence.
Abstract readLetterRandomized Controlled Trial
In one paragraph
Trial report in The New England journal of medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Opioid agonist treatment for people who are dependent on pharmaceutical opioids.The Cochrane database of systematic reviews · 2022Pooled it
- Interim opioid agonist treatment for opioid addiction: a systematic review.Harm reduction journal · 2022Pooled it
- Diversity inclusion in United States opioid pharmacological treatment trials: A systematic review.Experimental and clinical psychopharmacology · 2021Pooled it
- Novel intervention to improve food insecurity among individuals with opioid use disorder: A randomized clinical trial.Drug and alcohol dependence · 2025Trial
- Posttraumatic stress disorder in individuals seeking treatment for opioid use disorder in Vermont.Preventive medicine · 2021Trial
- Within-subject evaluation of interim buprenorphine treatment during waitlist delays.Drug and alcohol dependence · 2021Trial
- Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic.Journal of substance abuse treatment · 2021Trial
- MySafeRx: a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing for enhancing buprenorphine/naloxone adherence during opioid use disorder treatment: a pilot study.Addiction science & clinical practice · 2018Trial
- A novel mHealth application for improving HIV and Hepatitis C knowledge in individuals with opioid use disorder: A pilot study.Drug and alcohol dependence · 2018Trial
- Interim buprenorphine treatment during delays to comprehensive treatment: Changes in psychiatric symptoms.Experimental and clinical psychopharmacology · 2018Trial
- Unmet need for medication for opioid use disorder among persons who inject drugs in 23 U.S. cities.Drug and alcohol dependence · 2024Article
- Opioid treatment program culture and philosophy: Views of OTP staff and state officials on implementing interim methadone treatment.Journal of substance use and addiction treatment · 2024Article
- Racial Differences in Self-Report of Mental Illness and Mental Illness Treatment in the Community: An Analysis of Jail Intake Data.Administration and policy in mental health · 2023Article
- Technology-Assisted Buprenorphine Treatment in Rural and Nonrural Settings: Two Randomized Clinical Trials.JAMA network open · 2023Article
- Practical Technology for Expanding and Improving Substance Use Disorder Treatment: Telehealth, Remote Monitoring, and Digital Health Interventions.The Psychiatric clinics of North America · 2022Review
- Physician response to COVID-19-driven telehealth flexibility for opioid use disorder.The American journal of managed care · 2022Article
- Patients With Serious Injection Drug Use-Related Infections who Experience Patient-Directed Discharges on Oral Antibiotics Have High Rates of Antibiotic Adherence but Require Multidisciplinary Outpatient Support for Retention in Care.Open forum infectious diseases · 2022Article
- Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings : Harm Reduction in Outpatient Addiction Treatment.Journal of general internal medicine · 2021Review
- Challenges and opportunities during the COVID-19 pandemic: Treating patients for substance use disorders during the perinatal period.Preventive medicine · 2021Article
- Impact of Current Pain Status on Low-Barrier Buprenorphine Treatment Response Among Patients with Opioid Use Disorder.Pain medicine (Malden, Mass.) · 2021Article
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Stacey C SigmonUniversity of Vermont, Burlington, VT stacey.sigmon@uvm.edu.
Taylor A OchalekUniversity of Vermont, Burlington, VT stacey.sigmon@uvm.edu.
Andrew C MeyerUniversity of Vermont, Burlington, VT stacey.sigmon@uvm.edu.
Bryce HruskaUniversity of Vermont, Burlington, VT stacey.sigmon@uvm.edu.
Sarah H HeilUniversity of Vermont, Burlington, VT stacey.sigmon@uvm.edu.
Gary J BadgerUniversity of Vermont, Burlington, VT stacey.sigmon@uvm.edu.
Gail RoseUniversity of Vermont, Burlington, VT stacey.sigmon@uvm.edu.
John R BrooklynUniversity of Vermont, Burlington, VT stacey.sigmon@uvm.edu.
Robert P SchwartzFriends Research Institute, Baltimore, MD.
Brent A MooreYale University School of Medicine, New Haven, CT.
Stephen T HigginsUniversity of Vermont, Burlington, VT.
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MVermont Center on Behavior and HealthP20GM103644 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI KHADANGA, SHERRIE · 2013 to 2022
$21.3MTRAINING IN BEHAV. PHARMACOLOGY OF HUMAN DRUG DEPENDENCET32DA007242 · NIDA · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI HEIL, SARAH H, HIGGINS, STEPHEN T · 1990 to 2025
$8.2MAutomated Recovery Line for Medication Assisted TreatmentR01DA034678 · NIDA · YALE UNIVERSITY · PI MOORE, BRENT A. · 2013 to 2015
$1.2MInterim Treatment: Leveraging buprenophine + technology to bridge waitlist delaysR34DA037385 · NIDA · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI SIGMON, STACEY C · 2014 to 2015
$652kNCATS NIH HHS UL1 TR001863NIDA NIH HHS R01 DA034678NIDA NIH HHS R34 DA037385NIDA NIH HHS T32 DA007242NIGMS NIH HHS P20 GM103644
Abstract
PubMed holds no abstract for this paper.
Indexed as
Waiting ListsBuprenorphineHumansNarcotic AntagonistsOpioid-Related DisordersPilot ProjectsBuprenorphineNarcotic Antagonists
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.